Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.

Palmer, Adam C; Sorger, Peter K

Palmer, Adam C; Sorger, Peter K.

Affiliation

Palmer AC; Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, MA 02115, USA.
Sorger PK; Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, MA 02115, USA. Electronic address: peter_sorger@hms.harvard.edu.

Cell ; 171(7): 1678-1691.e13, 2017 Dec 14.

Article in En | MEDLINE | ID: mdl-29245013

Subject(s)

Antineoplastic Combined Chemotherapy Protocols; Neoplasms/drug therapy; Animals; Biological Variation, Individual; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Drug Resistance, Neoplasm; Heterografts; Humans; Immunotherapy; Neoplasm Transplantation

Key words

cancer; clinical trials; combination therapy; drug synergy; mathematical modeling; patient-derived tumor xenograft; pharmacology; systems biology; tumor heterogeneity

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Neoplasms Limits: Animals / Humans Language: En Journal: Cell Year: 2017 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google